A Single Dose of BRTX 100 for Patients With Chronic Lumbar Disc Disease (cLDD)

Recruiting now · Phase 2 · Has a placebo group

Conditions studied: Lumbar Disc Disease

In brief

This is a double-blind, controlled, randomized study with blinded assessments using a single dose. Subjects that have a current diagnosis of chronic lumbar disc disease and meet eligibility criteria will be enrolled. Chronic lumbar disc disease is defined as back and/or radicular pain with degeneration of the disc confirmed by patient history, physical examination, and radiographic measures such as computed tomography (CT), magnetic resonance imaging (MRI), plain film, myelography, discography, or other acceptable means.

Key facts

Study ID
NCT04042844
Run by
BioRestorative Therapies
People needed
99
Starts
2022-06-30
Expected to finish
2027-12-01
Last updated by the study team
2025-08-26

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

Where it is running

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.